Active (not recruiting) Phase 1 2024-511346-39-00

Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

Phase 1 – testing safety in a small group of people

Conditions: Immune-mediated necrotizing myopathy Antiphospholipid syndrome Behçet’s Syndrome Bullous pemphigoid Dermatomyositis Immune Thrombocytopenia

Sponsor: Chugai Pharmaceutical Co. Ltd.

trial.available_in:

БГ

Overview

Trial status: Authorised

Who can participate

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 78 participants

Locations 14

Austria (1)

Bulgaria (1)

Croatia (1)

Czech Republic (1)

France (1)

Germany (1)

Hungary (1)

Italy (1)

Netherlands (1)

Norway (1)

Poland (1)

Portugal (1)

Romania (1)

Spain (1)

Status

Active (not recruiting)

Phase

Phase 1

Study type

INTERVENTIONAL

Sex

Male and female

Minimum age

18 Years

Healthy volunteers

Start date

11.02.2025

Registry ID

2024-511346-39-00

Source

euclinicaltrials.eu

trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.